A new era for hemophilia B treatment

Jason Taylor, Rebecca Kruse-Jarres

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.

Original languageEnglish (US)
Pages (from-to)1734-1736
Number of pages3
JournalBlood
Volume127
Issue number14
DOIs
StatePublished - Apr 7 2016

Fingerprint

Hemophilia B
Factor IX
Recombinant Fusion Proteins
Half-Life
Albumins
Blood
Safety

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

A new era for hemophilia B treatment. / Taylor, Jason; Kruse-Jarres, Rebecca.

In: Blood, Vol. 127, No. 14, 07.04.2016, p. 1734-1736.

Research output: Contribution to journalArticle

Taylor, J & Kruse-Jarres, R 2016, 'A new era for hemophilia B treatment', Blood, vol. 127, no. 14, pp. 1734-1736. https://doi.org/10.1182/blood-2016-02-694869
Taylor, Jason ; Kruse-Jarres, Rebecca. / A new era for hemophilia B treatment. In: Blood. 2016 ; Vol. 127, No. 14. pp. 1734-1736.
@article{ea99beaaf462445eaff621ce082c062b,
title = "A new era for hemophilia B treatment",
abstract = "In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.",
author = "Jason Taylor and Rebecca Kruse-Jarres",
year = "2016",
month = "4",
day = "7",
doi = "10.1182/blood-2016-02-694869",
language = "English (US)",
volume = "127",
pages = "1734--1736",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "14",

}

TY - JOUR

T1 - A new era for hemophilia B treatment

AU - Taylor, Jason

AU - Kruse-Jarres, Rebecca

PY - 2016/4/7

Y1 - 2016/4/7

N2 - In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.

AB - In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.

UR - http://www.scopus.com/inward/record.url?scp=84963632274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963632274&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-02-694869

DO - 10.1182/blood-2016-02-694869

M3 - Article

C2 - 27056991

AN - SCOPUS:84963632274

VL - 127

SP - 1734

EP - 1736

JO - Blood

JF - Blood

SN - 0006-4971

IS - 14

ER -